KPV — Clinical Reference

**⚠ Educational reference only — not medical advice.** This article is for research and educational reference. Always consult your own physician before considering any peptide protocol. See the full Disclaimer at the end of this article. ## Introduction KPV (Lys-Pro-Val) is the C-terminal tripeptide of α-melanocyte-stimulating hormone (α-MSH). Unlike full-length α-MSH, KPV lacks pigmentary activity but retains the parent peptide's anti-inflammatory effects at epithelial surfaces. Investigational in the United States; widely cited in inflammatory-bowel and dermatologic research. ## Mechanism of Action KPV exerts anti-inflammatory activity by inhibiting NF-κB signaling, dampening pro-inflammatory cytokine production (TNF-α, IL-6, IL-1β), and stabilizing epithelial barriers. Effects are most pronounced at epithelial surfaces — gut, lung, skin — where local concentrations can be elevated by route choice. ## Research Indications Inflammatory bowel disease (ulcerative colitis, Crohn's research), inflammatory skin conditions (psoriasis, eczema research), wound healing, and adjunct in oral mucosal inflammation. ## Reconstitution Typical 5 mg lyophilized vial: add **2.5 mL of bacteriostatic water**, swirl gently. Final concentration **2000 mcg/mL (2 mg/mL)** — each 0.05 mL (5 units on a U-100 insulin syringe) delivers 100 mcg. ## Dosing Protocol (research literature) Research protocols typically dose **200–500 mcg subcutaneously once daily** or **300–500 mcg orally daily** in IBD research contexts. Oral KPV preparations leverage its small size to retain activity through GI transit. Cycle length **4–8 weeks** with symptom and biomarker reassessment. ## Administration Subcutaneous into abdominal fat for systemic protocols; oral capsule preparations (compounding pharmacy) for IBD-focused protocols; topical preparations in dermatologic research. ## Storage & Handling Lyophilized: refrigerate (2–8°C). Reconstituted: refrigerate; stable approximately **14–21 days**. Protect from light. ## Side Effects Generally well-tolerated in available reports. Most frequent: mild injection-site reaction (SC), transient mild gastrointestinal upset (oral). No melanocyte activation reported. ## Contraindications Pregnancy, lactation, active infectious enteritis (the anti-inflammatory effect could blunt appropriate host response). ## Monitoring Baseline indication-appropriate inflammation marker (CRP, fecal calprotectin for IBD; PASI/SCORAD for inflammatory skin disease). Re-measure at 4 and 8 weeks. ## Disclaimer **This article is for informational and research-reference purposes only.** Nothing in this document constitutes medical advice, a prescription, or a recommendation from a physician. The reconstitution, dosing, and protocol information above reflects ranges commonly cited in published research and clinician-directed protocols — it is provided as reference material only, not as instructions, an endorsement of off-label use, or a substitute for individualized medical evaluation. **Customers should do their own research and consult their own physician** before considering any peptide protocol. Whether a given compound is appropriate for an individual — and at what dose, for what duration, and alongside what monitoring — is a decision that only a licensed clinician with knowledge of that individual's medical history, current medications, and conditions can make. The platform and the author make no claim that any compound described here is safe, effective, or appropriate for any particular person or purpose, and accept no responsibility for outcomes arising from self-directed use of the information.